Seres Therapeutics(MCRB)

Search documents
Seres Therapeutics(MCRB) - 2019 Q4 - Annual Report
2020-03-02 15:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-4326290 (State or Other Jurisdiction ...
Seres Therapeutics (MCRB) Presents At Stifel Healthcare Conference - Slideshow
2019-11-20 10:08
| --- | --- | --- | --- | |-------|-----------------------------------|-------|-----------------------------| | | | | | | | | | | | | | | | | | | | Seres Therapeutics Overview | | | Stifel 2019 Healthcare Conference | | | | | November 19, 2019 | | | | | | | | | | | | | Forward looking statements | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------|-------------------| | | | | included herein repres ...
Seres Therapeutics(MCRB) - 2019 Q3 - Quarterly Report
2019-11-05 19:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other j ...
Seres Therapeutics(MCRB) - 2019 Q3 - Earnings Call Transcript
2019-11-05 17:56
Financial Data and Key Metrics Changes - The company reported a net loss of $16.4 million for Q3 2019, compared to a net loss of $21.9 million for the same period in 2018, indicating an improvement in financial performance [41] - The cash and cash equivalents at the end of Q3 2019 were approximately $83.8 million, which does not include recent debt financing [42] Business Line Data and Key Metrics Changes - The SER-287 Phase 2b study is ongoing, with a focus on patients with mild to moderate active ulcerative colitis, aiming to replicate positive results from the previous Phase 1b study [11][55] - The SER-109 ECOSPOR III Phase 3 study is over 85% enrolled, with top-line results expected in mid-2020 [26][80] Market Data and Key Metrics Changes - The company has strengthened its balance sheet with a $51 million equity raise and access to an additional $50 million in debt financing, positioning itself for a data-rich 2020 [8][9][47] Company Strategy and Development Direction - The company is focused on advancing its microbiome therapeutics platform and executing its promising pipeline of drug candidates, including collaborations with AstraZeneca in immuno-oncology [7][9][37] - The company aims to develop first-in-class microbiome therapeutics that provide non-immunosuppressive treatment options for serious diseases [12][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical studies and the unmet medical needs that their products aim to address, particularly in the context of SER-109 and SER-287 [53][86] - The company anticipates reaching multiple significant R&D milestones in 2020, which could be transformative for both the company and the industry [47][92] Other Important Information - The company has implemented disciplined financial management and streamlined operations to enhance efficiency and focus on key programs [46][92] - SER-109 has received breakthrough therapy and orphan drug designations from the FDA, highlighting its potential impact in treating recurrent C. difficile infection [26][27] Q&A Session Summary Question: Enrollment trends for the SER-109 trial - Management noted variability in month-to-month enrollment but expressed optimism as the study is nearing full enrollment, with over 85% completed [51][52] Question: Pros and cons of starting a second pivotal trial for SER-287 - Management indicated a focus on the ongoing 2b study and emphasized the importance of replicating previous positive data before considering additional trials [54][55] Question: Expectations for SER-401 Phase 1b data - Management highlighted the importance of evaluating safety and efficacy in the context of improving responses to checkpoint inhibitor therapies, particularly in metastatic melanoma [59][62] Question: Interactions with the FDA regarding donor-driven therapies - Management confirmed ongoing discussions with the FDA and emphasized the safety of their products compared to unregulated FMT [67][70] Question: Gating factors for SER-301 IND filing - Management outlined the final stages of design and manufacturing for SER-301, with plans to initiate clinical development in early 2020 [78][79] Question: Confidence in SER-109 timing for results - Management reiterated confidence in the timing of SER-109 results due to the high enrollment rate and the significance of the upcoming data [80][81] Question: Additional cash and focus on current programs - Management confirmed a focus on current programs and the potential for transformative results in the upcoming year, while remaining open to exploring new opportunities [90][92]
Seres Therapeutics(MCRB) - 2019 Q2 - Quarterly Report
2019-08-06 15:18
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other jurisd ...
Seres Therapeutics(MCRB) - 2019 Q1 - Quarterly Report
2019-05-02 13:52
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37465 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 27-4326290 (State or other juris ...
Seres Therapeutics(MCRB) - 2018 Q4 - Annual Report
2019-03-06 16:19
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37465 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 27-4326290 (State or Other Jurisdiction of Incorporation or Organization) 200 Sidney Street – 4th Floor Cambridge, Massachusetts 02139 (Address of Principal Executive Offices) (Zip Code) (IRS Employer Identifica ...